Pulling out the stops on personalised medicine
This article was originally published in RAJ Devices
Executive Summary
Personalised medicine is set to become big business. Biopharmaceutical companies of all sizes have personalised medicine projects in their early pipeline. Regulators in the EU and the US are drafting guidelines on biomarkers and companion diagnostics, and government funding is being made available for collaborative industry/academia projects.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.